April 2024

Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1, which was well toleratedFollowing efforts to optimize allogeneic CAR-T therapy, Poseida is presenting a new data analysis u

Encino acquires all data from orbits covering North America from SATLANTIS’ GEISAT to provide to North & South American clients in one of the largest commercial contracts for satellite-based methane emissions monitoring. SATLANTIS successfully launches HORACIO, its sixth successful mission

Results from this training dataset demonstrate potential for Adela’s MRD test to inform adjuvant treatment decisions and monitor for recurrence in patients with HPV-positive and HPV-negative head & neck cancer FOSTER CITY, Calif., April 8, 2024 /PRNewswire/ — Adela, Inc., an innovato

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: